Investigating how MARCH5 affects cell death in acute myeloid leukemia
Official title: Characterizing the role of MARCH5 in apoptosis regulation in acute myeloid leukemia
Funded at Seattle Children's Hospital · NIH-11072998 · Data updated 2026-11-12
This study is looking at a protein called MARCH5 to see how it helps leukemia cells survive, with the hope that blocking it could make current treatments work better for people with acute myeloid leukemia (AML).
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Seattle Children's Hospital NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | April 1, 2024 |
| Project end | March 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $248,979 |
| NIH project number | 5R00CA263161-04 |
| Project ID | NIH-11072998 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with acute myeloid leukemia who may benefit from novel treatment strategies.
✕Less likely to help
Patients with other types of leukemia or those who are not eligible for experimental therapies may not receive benefits from this research.
What this research studies
This research focuses on understanding the role of a protein called MARCH5 in regulating cell death in acute myeloid leukemia (AML). By using advanced techniques like CRISPR-Cas9, the researchers aim to identify how MARCH5 contributes to the survival of leukemia cells and how its inhibition could enhance the effectiveness of existing treatments like venetoclax. The study will explore the mechanisms by which MARCH5 prevents apoptosis, potentially leading to new therapeutic strategies for AML patients. If successful, this research could pave the way for innovative treatments that target MARCH5 to improve patient outcomes.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that improve survival rates for patients with acute myeloid leukemia.
How similar studies have gone: Previous research has shown promising results in targeting apoptosis pathways in leukemia, suggesting that this approach may be effective.
Where this research is happening
-
Seattle Children's Hospital
Seattle, United States Active
Researchers
- Principal investigator: Lin, Shan — Seattle Children's Hospital
- Study coordinator: Lin, Shan
Related research
Other NIH-funded projects on the same topics.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Interferon-γ plus donor immune cells to fight AML/MDS after partial donor transplant
This project tests a therapy that adds a signaling protein, IFN-γ, with donor immune cells to help treat relapsed AML/MDS after a haploidentical stem cell transplant.
-
Targeting the protein housekeeping system in adult leukemia
Researchers are testing a new approach to treat acute myeloid leukemia by disrupting how AML cells manage their proteins, with the goal of helping patients live longer and healthier lives.
-
Understanding how epigenetic helper proteins drive AML and how to target them
A scientist team is studying how accessory proteins in gene-regulating complexes affect acute myeloid leukemia and whether they can be targeted for safer, more precise therapies.
-
Targeting FLVCR1-enabled choline use in a aggressive AML subtype
A new approach aims to block how a specific leukemia subtype (CG-AML) takes up choline to feed its growth, potentially slowing or stopping the disease.
-
Advancing CD70-targeted CAR-NK Therapy for AML
A patient-focused look at a new cell therapy that uses engineered NK cells to target AML by hitting CD70, aiming to reduce relapse with potentially fewer blood cell problems.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.